Daan Gilissen

Mr. Daan Gilissen

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
JVJeron Venhuizen
Jeron Venhuizen
MBMaaike G. J. M. van Bergen
Maaike G. J. M. van Bergen
SBSaskia M. Bergevoet
Saskia M. Bergevoet
DGDaan Gilissen
Daan Gilissen
CSCornelia G. Spruijt
Cornelia G. Spruijt
BRB. A. van der Van der Reijden
B. A. van der Van der Reijden
The transcription factor Growth Factor Independence 1B (GFI1B) recruits Lysine Specific Demethylase 1 A (LSD1/KDM1A) to stimulate gene programs relevant for megakaryocyte and platelet biology. Inherited pathogenic GFI1B variants result in thrombocytopenia and bleeding propensities with varying intensity. Whether these affect similar gene programs is unknow. Here we studied transcriptomic effects of four patient-derived GFI1B variants (GFI1BT174N,H181Y,R184P,Q287*) in MEG01 megakaryoblasts. Compared to normal GFI1B, each variant affected different gene programs with GFI1BQ287* uniquely failing to repress myeloid traits. In line with this, single cell RNA-sequencing of induced pluripotent stem cell (iPSC)-derived megakaryocytes revealed a 4.5-fold decrease in the megakaryocyte/myeloid cell ratio in GFI1BQ287* versus normal conditions. Inhibiting the GFI1B-LSD1 interaction with small molecule GSK-LSD1 resulted in activation of myeloid genes in normal iPSC-derived megakaryocytes similar to what was observed for GFI1BQ287* iPSC-derived megakaryocytes. Thus, GFI1B and LSD1 facilitate gene programs relevant for megakaryopoiesis while simultaneously repressing programs that induce myeloid differentiation.

18 February 2023 in Leukemia
Verified
Journal Article
Closed access
PDF file
SASaioa Arza-Apalategi
Saioa Arza-Apalategi
BHBranco M. H. Heuts
Branco M. H. Heuts
MDMeike T. M. Dooijes
Meike T. M. Dooijes
DGDaan Gilissen
Daan Gilissen
AHAdrian J. P. van der Heijden
Adrian J. P. van der Heijden
BRB. A. van der Van der Reijden
B. A. van der Van der Reijden

4 December 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
SASaioa Arza-Apalategi
Saioa Arza-Apalategi
BHBranco M. H. Heuts
Branco M. H. Heuts
SBSaskia M. Bergevoet
Saskia M. Bergevoet
RMRoos Meering
Roos Meering
DGDaan Gilissen
Daan Gilissen
BRB. A. van der Van der Reijden
B. A. van der Van der Reijden

27 May 2026 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
SASaioa Arza-Apalategi
Saioa Arza-Apalategi
DGDaan Gilissen
Daan Gilissen
AGAnne C van der Grinten
Anne C van der Grinten
SOSeline Natalie Van den Oever
Seline Natalie Van den Oever
EAErik van den Akker
Erik van den Akker
BRB. A. van der Van der Reijden
B. A. van der Van der Reijden
Background/Objectives: Acute myeloid leukemia (AML) comprises genetic subclasses with distinct gene expression profiles. While AML gene expression studies have mainly focused on protein-coding genes, our understanding of expression patterns of long intergenic noncoding RNAs (lincRNAs) remains incomplete. This is due to limited sample sizes, as well as incomplete annotation of lncRNAs with context-dependent expression. Methods: To address this gap, we developed the bioinformatic pipeline LIRA (long intergenic noncoding RNA annotator) to identify novel lincRNAs using stringent criteria, including spliced and intergenic transcripts, and algorithms to exclude coding potential. Results: By applying LIRA to RNA-sequencing data from 878 pediatric and adult AML cases and 20 healthy controls, we identified 1560 novel lincRNAs, expanding the GENCODE v38 lincRNA catalog by 27%. Integration of in-house-generated CAGE- and ChIP-sequencing data from KMT2A::MLLT3 samples revealed that 80% of the novel lincRNAs are 5′ capped, and at least 67% harbor activating epigenetic marks at their transcription start sites. Unsupervised analysis of the 1000 most variable known and newly identified lincRNAs uncovered subclass-specific expression patterns, mirroring those observed for protein-coding genes. Weighted Gene Co-expression Network Analysis identified 17 lincRNA expression modules associated with AML subclasses. Notably, expression of these modules decreased upon degradation of the leukemogenic onco-fusion proteins KMT2A::MLLT3 and PML::RARA, indicating that lincRNA expression is responsive to oncogenic signaling. Conclusions: This comprehensive analysis shows that lincRNAs exhibit similar subclass-specific expression patterns as protein-coding genes and establishes a valuable resource for future studies on genetically defined AML subclasses, with potential implications for biomarker discovery and therapeutic targeting.